Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINHALATIONStandard

TRELEGY ELLIPTA

FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE

Standard Dose
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview TRELEGY ELLIPTA is listed in Drugs@FDA under application 209482 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE Form and strength POWDER;INHALATION - 0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH Sponsor GLAXOSMITHKLINE Submission history Latest submission status date: 2023-06-02 00:00:00.

Structured Monograph

Clinical summary

Approval overview TRELEGY ELLIPTA is listed in Drugs@FDA under application 209482 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE Form and strength POWDER;INHALATION - 0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH Sponsor GLAXOSMITHKLINE Submission history Latest submission status date: 2023-06-02 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
TRELEGY ELLIPTA (FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE) | Drug Monograph | MedicHelpline